Page 1

1 Hypera pharma Hypera Pharma increases Net Revenue by 50.0 % and EBITDA from Continuing Operations by 47.6 % in 3Q21 , with organic market - share¹ expansion for the fourth consecutive quarter - São Paulo , October 22 , 2021 – Hypera S.A. ( " Hypera Pharma " or " Company " ; B3 : HYPE3 ; Bloomberg : HYPE3 BZ ; ISIN : BRHYPEACNORO ; Reuters : HYPE3.SA ; ADR : HYPMY ) announces its financial results for the 3rd quarter of 2021. Financial data disclosed here are taken from the consolidated financial statements of Hypera S.A. , prepared in accordance with the Brazilian Accounting Pronouncement Committee ( CPC ) and International Financial Reporting Standards ( IFRS ) issued by the International Accounting Standards Board ( IASB ) . 3Q21 Highlights • Net revenue of R $ 1,632.6 million in the quarter , or 50.0 % higher than 3Q20 • EBITDA from Continuing Operations of R $ 580.9 million in 3Q21 , or 47.6 % higher than 3Q20 • Net Income from Continuing Operations of R $ 464.7 million , an increase of 32.9 % over 3Q20 • Organic sell - out growth of 13.7 % in 3Q21 , or 1.4 p.p. above the market² • Highest ever recorded Operating Cash Flow of R $ 539.9 million in the quarter , versus R $ 465.1 million in 3Q20 Interest on Equity approval of R $ 194.8 million in 3Q21 , or 5 % greater than 3Q20 Table 1 ( R $ million ) 3Q20 % NR 3Q21 % NR A % 9M20 % NR 9M21 % NR A % Gross Revenue , net of Returns and Unconditional Discounts 1,235.2 113.5 % 1,865.0 114.2 % 51.0 % Net Revenue 1,088.5 Gross Profit 696.3 100.0 % 1,632.6 64.0 % 1,043.5 100.0 % 63.9 % 49.9 % 50.0 % 3,348.1 113.3 % 2,954.0 100.0 % 4,310.9 1,929.6 65.3 % 2,784.0 4,922.2 114.2 % 100.0 % 47.0 % 45.9 % 64.6 % 44.3 % SG & A ( ex - Marketing and R & D ) Marketing ( 145.9 ) -13.4 % ( 192.4 ) ( 202.6 ) -18.6 % ( 275.0 ) -11.8 % 31.9 % ( 445.3 ) -15.1 % ( 541.3 ) -12.6 % 21.5 % -16.8 % 35.8 % EBITDA from Continuing Operations 393.5 36.1 % 580.9 35.6 % 47.6 % ( 572.3 ) -19.4 % ( 788.0 ) -18.3 % 1,091.4 37.7 % 36.9 % 1,534.8 35.6 % 40.6 % Net Income from Continuing Operations 349.6 32.1 % 464.7 28.5 % 32.9 % 996.7 Cash Flow from Operations 465.1 42.7 % 539.9 33.1 % 16.1 % 987.8 33.7 % 1,251.8 33.4 % 1,098.1 25.5 % 29.0 % 25.6 % 11.2 % EARNINGS CONFERENCE CALL - PORTUGUESE : 10/25/2021 , 11am ( Brasília ) / 10am ( New York ) Webcast : click here / Phone : +55 11 4090-1621 ( code - Hypera ) Replay : +55 ( 11 ) 3193-1012 or +55 ( 11 ) 2820-4012 ( code - 5476238 # ) or website ir.hypera.com EARNINGS CONFERENCE CALL - ENGLISH ( Simultaneous translation ) : 10/25/2021 , 11am ( Brasília ) / 10am ( New York ) Webcast : click here / Phone : US Toll Free +1 412 717-9627 ( code - Hypera ) Replay : +55 ( 11 ) 3193-1012 ( code - 8440138 # ) or website ir.hypera.com Note : ( 1 ) Sell - out PPP 3Q21 ( Pharmacy Purchase Price ) , as informed by IQVIA , considers the average purchase price from pharmacies and chains . It does not consider the sell - out of the Buscopan brands and the portfolio acquired from Takeda ; ( 2 ) As informed by IQVIA , it excludes the infant formula segment IR contacts +55 ( 11 ) 3627-4206 +55 ( 11 ) 3627-4097 ri@hypera.com.br